



















































114. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Apr 08]. Available from: <https://www.who.int/news/item/07-04-2021-interim-statement-of-the-covid-19-subcommittee-of-the-who-global-advisory-committee-on-vaccine-safety>
115. World Health Organization. Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 vaccine (Vaxzevria and Covishield) [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Apr 16]. Available from: [https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-\(gacvs\)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-\(vaxzevria-and-covishield\)](https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield))
116. European Medicines Agency. COVID-9 vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets [Internet]. 20/04/2021. Amsterdam: European Medicines Agency; 2021 [cited 2021 Apr 20]. Available from: <https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>
117. European Medicines Agency. COVID-19 vaccine safety update: COVID-19 vaccine Janssen [Internet]. Amsterdam: European Medicines Agency; 2021 [cited 2021 Apr 26]. Available from: [https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-22-april-2021\\_en.pdf](https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-22-april-2021_en.pdf)

## Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots – vaccine safety surveillance in action. Toronto, ON: Queen’s Printer for Ontario; 2021.

## Disclaimer

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

## Public Health Ontario

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit [publichealthontario.ca](https://publichealthontario.ca).

